Compare iShares MBS ETF (MBB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs TG Therapeutics Inc — how do they compare? iShares MBS ETF trades at $89.79 (market cap $35.41B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: iShares MBS ETF is far larger — about 4.3× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and TG Therapeutics Inc for 16 Days on average.
| MBB | TGTX | |
|---|---|---|
Market Cap | $35.41B | $8.16B |
Volume | 5,388,525 | 1,735,121 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $59.06 |
52-Week Low | $89.09 | $26.94 |
Typical Hold Time | 96 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.79, up 0.64% with bearish technical signals from moving averages and ADX indicators. The ETF faces headwinds from rising intermediate-term rates and inflation pressures, with short interest surging 98.3% in September. Recent institutional buying by Corient Private Wealth and Baird Financial contrasts with technical weakness and negative analyst commentary on duration risk.
Outlook remains cautious due to interest rate sensitivity and convexity risks in mortgage-backed securities. The 5.68-year effective duration exposes MBB to Fed policy shifts, though Norway's $2.3 trillion sovereign fund rotation into MBS provides counterbalancing institutional support. Key risks include prepayment optionality and persistent inflation eroding real returns.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
